Dapagliflozin for patients with heart failure and reduced ejection fraction

The CDC estimates that national costs related to heart failure exceed $30 billion annually. Clinicians and researchers continue to aggressively pursue measures aimed at reducing morbidity and mortality among the 6.5 million adults affected by the disease. Dapagliflozin recently emerged as a promising FDA-approved therapy for patients with systolic heart failure, more commonly referred to as heart failure with reduced ejection fraction.
Source: Journal of the American Academy of Physician Assistants - Category: Primary Care Tags: Special Article Source Type: research